Bernstein raised the firm’s price target on Gilead (GILD) to $135 from $120 and keeps an Outperform rating on the shares. Gilead reported Q2 revenue and EPS that slightly beat estimates, while the full year guidance was raised as HIV performed better than expected, the analyst tells investors in a research note. The firm says Yeztugo is off to a “great” start.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead upgraded to Outperform from Neutral at Daiwa
- Gilead Sciences Appoints New Senior Vice President
- Gilead Sciences’ Phase 3 Study on Triple Negative Breast Cancer: A Potential Game-Changer?
- Gilead Sciences: Hold Rating Amidst Strong HIV Performance and Limited Growth Prospects
- Gilead Sciences: Strong Q2 Performance and Promising Yeztugo Launch Support Buy Rating